menu
    • menu

    Company profile for Visen Pharmaceuticals

    Suanfarma, at the Core of a Better Life.

    Virtual Booth

    Contact Supplier

    Jai Radhe Sales is your partner for all your sourcing needs.

    Virtual Booth

    Contact Supplier

    Centrient is a leading manufacturer of Beta-Lactam Antibiotics and a provider of next-generation Statins and Antifungals.

    Virtual Booth

    Contact Supplier

    Moehs Group, a reference company in the production of pharmaceutical active ingredients.

    Virtual Booth

    Contact Supplier

    Biophore is a research-driven global pharmaceutical company focused on niche APIs for the generic industry.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2025-11-03

    Virtual Booth

    Contact Supplier

    EVENTS

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass

    Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

    Update your Virtual Booth on PharmaCompass, ask us

    About

    Visen Pharmaceuticals is a biotech company focused on developing and commercializing innovative endocrine drugs.Visen Pharmaceuticals is a biotech company focused on developing and commercializing innovative endocrine drugs that address significant unmet needs for patients in Greater China.

    List your booth number for exhibitions, ask us

    CONTACT DETAILS

    Click the arrow to open the dropdown
    Contact SupplierContact
    Google MapGoogle Map
    Full View ScreenFull View Screen
    Visen PharmaceuticalsChina Flag
    Country
    Country
    China
    Address
    Address
    1788 Nanjing West Road, Jing'an District, Shanghai, China
    Telephone
    Telephone
    +86 021 5299 9605
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    http://www.visenpharma.com/
    Linkedin
    Linkedin
    youtube
    YouTube
    Twitter
    Twitter

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Events

    Webinars & Exhibitions

    Request a meetingRequest a meeting
    Full Screen ViewFull Screen View
    Tides Asia

    Tides Asia

    Not Confirmed

    envelop Contact Supplier

    Tides Asia

    Post an Enquiry

    Meeting

    Digital content

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Visen Pharmaceuticals files for $86M IPO in Hong Kong
    Visen Pharmaceuticals files for $86M IPO in Hong Kong

    22 Mar 2025

    // FIERCE PHARMA

    https://www.fiercepharma.com/pharma/biotech-designed-commercialize-ascendis-endocrinology-drugs-china-files-86m-ipo

    FIERCE PHARMA
    22 Mar 2025
    Share Share
    VISEN's Palopegteriparatide Meets Endpoints In Phase 3 China Trial
    VISEN's Palopegteriparatide Meets Endpoints In Phase 3 China Trial

    12 Aug 2024

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/visen-pharmaceuticals-announced-that-the-phase-3-pathway-china-trial-of-palopegteriparatide-achieved-primary-and-key-secondary-endpoints-in-the-treatment-of-adults-with-hypoparathyroidism-302219715.html

    PR NEWSWIRE
    12 Aug 2024
    Share Share
    VISEN Announces Acceptance of a BLA for Lonapegsomatropin in China
    VISEN Announces Acceptance of a BLA for Lonapegsomatropin in China

    07 Mar 2024

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/visen-announces-acceptance-of-a-biologics-license-application-for-lonapegsomatropin-in-china-302082740.html

    PR NEWSWIRE
    07 Mar 2024
    Share Share
    Double-blind period completes! Primary endpoint analysis of ph 3 clinical trial
    Double-blind period completes! Primary endpoint analysis of ph 3 clinical trial

    06 Jan 2023

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/double-blind-period-completes-primary-endpoint-analysis-of-phase-3-clinical-trial-to-be-conducted-for-chinas-first-hormone-replacement-treatment-targeting-hypoparathyroidism-301715285.html

    PR NEWSWIRE
    06 Jan 2023
    Share Share
    VISEN Discloses 52-week Results for China Phase 3 Trial of Lonapegsomatropin
    VISEN Discloses 52-week Results for China Phase 3 Trial of Lonapegsomatropin

    17 Nov 2022

    // PRNEWSWIRE

    https://www.prnewswire.com/news-releases/visen-discloses-52-week-clinical-results-for-its-china-phase-3-trial-of-lonapegsomatropin-301681121.html

    PRNEWSWIRE
    17 Nov 2022
    Share Share
    Positive Results from VISEN's Phase 3 Trial of Once-Weekly TransCon hGH
    Positive Results from VISEN's Phase 3 Trial of Once-Weekly TransCon hGH

    23 May 2022

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2022/05/23/2448375/0/en/Positive-Results-from-VISEN-s-Phase-3-Trial-of-Once-Weekly-TransCon-hGH-in-China-Consistent-with-Ascendis-Pharma-s-Phase-3-Height-Trial.html

    GLOBENEWSWIRE
    23 May 2022
    Share Share

    ABOUT THIS PAGE

    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty
    • Privacy policy
    • Terms and conditions
    • Disclaimers
    • LinkedIn
    • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search